Despite the remarkable progresses achieved in the last two decades in understanding the pathophysiology of stroke, tissue-type plasminogen activator (tPA) remains the sole therapeutics approved by the US FDA for the treatment of acute ischemic stroke. The gene discussed is PLAT; the disease is Stroke.